JP7692832B2 - 併用医薬による糖尿病の治療又は予防方法 - Google Patents

併用医薬による糖尿病の治療又は予防方法 Download PDF

Info

Publication number
JP7692832B2
JP7692832B2 JP2021544029A JP2021544029A JP7692832B2 JP 7692832 B2 JP7692832 B2 JP 7692832B2 JP 2021544029 A JP2021544029 A JP 2021544029A JP 2021544029 A JP2021544029 A JP 2021544029A JP 7692832 B2 JP7692832 B2 JP 7692832B2
Authority
JP
Japan
Prior art keywords
compound
alkyl
formula
inhibitor
pharma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021544029A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021045159A1 (https=
JPWO2021045159A5 (https=
Inventor
泰子 米良
壮平 勝見
千尋 大熊
誠也 持田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Tobacco Inc
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of JPWO2021045159A1 publication Critical patent/JPWO2021045159A1/ja
Publication of JPWO2021045159A5 publication Critical patent/JPWO2021045159A5/ja
Priority to JP2025050332A priority Critical patent/JP2025094217A/ja
Application granted granted Critical
Publication of JP7692832B2 publication Critical patent/JP7692832B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021544029A 2019-09-04 2020-09-03 併用医薬による糖尿病の治療又は予防方法 Active JP7692832B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025050332A JP2025094217A (ja) 2019-09-04 2025-03-25 併用医薬による糖尿病の治療又は予防方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019161526 2019-09-04
JP2019161526 2019-09-04
PCT/JP2020/033463 WO2021045159A1 (ja) 2019-09-04 2020-09-03 併用医薬による糖尿病の治療又は予防方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025050332A Division JP2025094217A (ja) 2019-09-04 2025-03-25 併用医薬による糖尿病の治療又は予防方法

Publications (3)

Publication Number Publication Date
JPWO2021045159A1 JPWO2021045159A1 (https=) 2021-03-11
JPWO2021045159A5 JPWO2021045159A5 (https=) 2023-09-11
JP7692832B2 true JP7692832B2 (ja) 2025-06-16

Family

ID=74852211

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021544029A Active JP7692832B2 (ja) 2019-09-04 2020-09-03 併用医薬による糖尿病の治療又は予防方法
JP2025050332A Withdrawn JP2025094217A (ja) 2019-09-04 2025-03-25 併用医薬による糖尿病の治療又は予防方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025050332A Withdrawn JP2025094217A (ja) 2019-09-04 2025-03-25 併用医薬による糖尿病の治療又は予防方法

Country Status (10)

Country Link
US (1) US20230119894A1 (https=)
EP (2) EP4026564A4 (https=)
JP (2) JP7692832B2 (https=)
KR (1) KR20220056219A (https=)
CN (2) CN119113123A (https=)
AU (1) AU2020341926B2 (https=)
BR (1) BR112022003323A2 (https=)
CA (1) CA3151909A1 (https=)
MX (1) MX2022002683A (https=)
WO (1) WO2021045159A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7760370B2 (ja) * 2019-09-04 2025-10-27 日本たばこ産業株式会社 慢性腎臓病の治療又は予防方法
CA3175131A1 (en) * 2020-03-19 2021-09-23 Chihiro Okuma Treatment or prevention method for chronic heart failure
AU2022340358A1 (en) * 2021-09-02 2024-01-04 Daewoong Therapeutics Inc. Pharmaceutical composition for preventing or treating diabetic eye disease comprising sglt-2 inhibitor
WO2025245592A1 (en) * 2024-05-31 2025-12-04 Aché Laboratórios Farmacêuticos S.A. Multi-target compounds, process for the preparation of the compounds, intermediates, pharmaceutical composition, pharmaceutically acceptable salts, combination, medicament, use of a compound and method of treatment

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011002011A1 (ja) 2009-07-01 2011-01-06 キッセイ薬品工業株式会社 Sglt1阻害薬とdpp-iv阻害薬を組み合わせてなる医薬
JP2015516419A (ja) 2012-05-10 2015-06-11 イーライ リリー アンド カンパニー Ｓｇｌｔ１阻害剤としてのピラゾール化合物
JP2018115216A (ja) 2011-08-31 2018-07-26 日本たばこ産業株式会社 ピラゾール化合物及びその医薬用途
JP7130588B2 (ja) 2018-04-04 2022-09-05 日本たばこ産業株式会社 ヘテロアリールで置換されたピラゾール化合物及びその医薬用途
JP7206132B2 (ja) 2018-03-01 2023-01-17 日本たばこ産業株式会社 メチルラクタム環化合物及びその医薬用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI562775B (en) * 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
CN110066302B (zh) * 2018-01-23 2022-12-27 广东东阳光药业有限公司 吡喃葡萄糖基衍生物及其用途
JP7760370B2 (ja) * 2019-09-04 2025-10-27 日本たばこ産業株式会社 慢性腎臓病の治療又は予防方法
CA3175131A1 (en) * 2020-03-19 2021-09-23 Chihiro Okuma Treatment or prevention method for chronic heart failure

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011002011A1 (ja) 2009-07-01 2011-01-06 キッセイ薬品工業株式会社 Sglt1阻害薬とdpp-iv阻害薬を組み合わせてなる医薬
JP2018115216A (ja) 2011-08-31 2018-07-26 日本たばこ産業株式会社 ピラゾール化合物及びその医薬用途
JP2015516419A (ja) 2012-05-10 2015-06-11 イーライ リリー アンド カンパニー Ｓｇｌｔ１阻害剤としてのピラゾール化合物
JP7206132B2 (ja) 2018-03-01 2023-01-17 日本たばこ産業株式会社 メチルラクタム環化合物及びその医薬用途
JP7130588B2 (ja) 2018-04-04 2022-09-05 日本たばこ産業株式会社 ヘテロアリールで置換されたピラゾール化合物及びその医薬用途

Also Published As

Publication number Publication date
BR112022003323A2 (pt) 2022-05-24
US20230119894A1 (en) 2023-04-20
AU2020341926A1 (en) 2022-03-17
EP4342466A1 (en) 2024-03-27
AU2020341926B2 (en) 2026-02-26
EP4026564A1 (en) 2022-07-13
KR20220056219A (ko) 2022-05-04
JP2025094217A (ja) 2025-06-24
JPWO2021045159A1 (https=) 2021-03-11
MX2022002683A (es) 2022-04-07
CA3151909A1 (en) 2021-03-11
WO2021045159A1 (ja) 2021-03-11
EP4026564A4 (en) 2023-03-15
CN114585387B (zh) 2024-10-29
CN114585387A (zh) 2022-06-03
CN119113123A (zh) 2024-12-13

Similar Documents

Publication Publication Date Title
JP7692832B2 (ja) 併用医薬による糖尿病の治療又は予防方法
JP2021526123A (ja) オートタキシン阻害剤とその使用
US20160115168A1 (en) Novel fused pyrimidine compound or salt thereof
JP7130588B2 (ja) ヘテロアリールで置換されたピラゾール化合物及びその医薬用途
JP2025026615A (ja) メチルラクタム環化合物及びその医薬用途
JP2025138791A (ja) 慢性腎臓病の治療又は予防方法
WO2022092141A1 (ja) 抗ウイルス活性を有するアミド誘導体
RU2857384C2 (ru) Способ лечения или профилактики диабета с помощью комбинированной медицины
HK40067960A (en) Therapeutic or prophylactic method for diabetes using combination medicine
HK40068410A (en) Chronic kidney disease treatment or prevention method
RU2809634C2 (ru) Соединение с метиллактамным кольцом и его применение в фармацевтике
HK40044833A (en) Methyllactam ring compound and medicinal use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230901

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240813

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241204

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250502

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250527

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250604

R150 Certificate of patent or registration of utility model

Ref document number: 7692832

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350